Almirall, S.A.

Almirall, S.A. is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals. Its operations span Europe, the United States, and various international markets. The company provides treatments targeting a wide array of skin conditions, including actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and several orphan indications. Beyond its core dermatological focus, Almirall also extends its offerings to other therapeutic areas, such as cardiovascular, musculoskeletal, respiratory, and neurological disorders; alimentary tract and metabolic conditions; systemic anti-infectives; genitourinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Among its key products are Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. The company fosters numerous collaborations and strategic alliances with partners such as Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. Originally established as Laboratorios Almirall, S.A. in 1943, the company adopted its current name, Almirall, S.A., in May 2009, and is headquartered in Barcelona, Spain.